A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[N,N-bis(2-hydroxyethyl)amino]phenyl chloroformate

Tetrahedron Letters

Volumn 46, Issue 40, 2005, Pages 6919-6922

  Niculescu Duvaz, Dan ^a   Scanlon, Ian ^a   Niculescu Duvaz, Ion ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antibody directed enzyme prodrug therapy; Chloroformate; Prodrug; Scale up synthesis; Silyl protection

Indexed keywords

4 [N,N BIS(2 HYDROXYETHYL)AMINO]PHENYL CHLOROFORMATE; BENZENE DERIVATIVE; ETHER DERIVATIVE; GLUTAMIC ACID DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG; ZD2767P;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; DEPROTECTION REACTION; DRUG STRUCTURE; DRUG SYNTHESIS;

EID: 27744513395     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2005.08.003     Document Type: Article

References (20)

1. Niculescu-Duvaz, I; Springer, C. Curr. Med. Chem. 1995, 2, 687-706.
2. Niculescu-Duvaz, I; Springer, C. Introduction to the background, principles and state of the art in suicide gene therapy. In Suicide Gene Therapy, Springer, C., Ed.; Humana Press: New Jersey, 2004; pp 1-27.
3. Niculescu-Duvaz, D.; Niculescu-Duvaz, I; Springer, C. Design of prodrugs for suicide gene therapy. In Suicide Gene Therapy, Springer, C., Ed.; Humana Press: New Jersey, 2004; pp 161-202.
4. Niculescu-Duvaz, D.; Niculescu-Duvaz, I; Friedlos, F.; Martin, J.; Lehouritis, P.; Marais, R.; Springer, C. J. J. Med. Chem. 2003, 46, 1690-1705.
5. Niculescu-Duvaz, I; Scanlon, I; Niculescu-Duvaz, D.; Friedlos, F.; Martin, J.; Marais, R.; Springer, C. J. J. Med. Chem. 2004, 47, 2651-2658.
6. Burke, P. J.; Dowell, R. I; Mauger, A. B.; Springer, C. J. Amino acid-linked nitrogen mustard derivatives and their use as carboxypeptidase G2-activated prodrugs in the treatment of tumors. In PCT Int. Appl. WO 9402450, 1994.
7. Springer, C. J.; Dowell, R.; Burke, P. J.; Hadley, E.; Davies, D. H.; Blakey, D. C.; Melton, R. G.; Niculescu-Duvaz, I. J. Med. Chem. 1995, 38, 5051-5065.
8. Springer, C. J.; Marais, R. Surface expression of enzyme in gene directed prodrug therapy. In PCT Int. Appl. WO 9603515, 1996.
9. Blakey, D. C.; Burke, P. J.; Davies, D. H.; Dowell, R. L.; East, S. J.; Eckersley, K. P.; Fitton, J. E.; McDaid, J.; Melton, R. G.; Niculescu-Duvaz, I; Pinder, P. E.; Sharma, S. K.; Wright, A. F.; Springer, C. J. Cancer Res. 1996, 56, 3287-3292.
10. Emery, S. C.; Blakey, D. C. Fusion proteins of prodrug activating enzymes and targeting moieties and their therapeutic uses. In PCT Int. Appl. WO 9851787, 1998.
11. Friedlos, F.; Davies, L.; Scanlon, I; Ogilvie, L.; Martin, J.; Stribbling, S.; Spooner, R.; Niculescu-Duvaz, I; Marais, R.; Springer, C. Cancer Res. 2002, 62, 1724-1729.
12. Webley, S.; Francis, R.; Pedley, R.; Sharma, S.; Begent, R.; Hartley, J.; Hochhauser, D. British J. Cancer 2001, 84, 1671-1676.
13. Francis, R. J.; Sharma, S. K.; Springer, C. J.; Green, A. J.; Hope-Stone, L. D.; Sena, L.; Martin, J.; Adamson, K. L.; Robins, A.; Gumbrell, L.; O'Malley, D.; Tsiompanou, E.; Shahbakhti, H.; Webley, S.; Hochhauser, D.; Hilson, A. J.; Blakey, D.; Begent, R. H. J. British J. Cancer 2002, 87, 600-607.
14. Mayer, A.; Francis, R.; Sharma, S. K.; Sully, C.; Parker, S.; Tolner, B.; Griffin, N.; Germain, M.; Beckett, P.; Boxer, G.; Green, A.; Chester, K. A.; Begent, R. H. J. British J. Cancer 2004, 91, S8.
15. Sharma, S.; Pedley, R.; Bhatia, J.; Boxer, G.; El-Emir, E.; Qureshi, U.; Tolner, B.; Lowe, H.; Michael, N.; Minton, N.; Begent, R.; Chester, K. Clin. Cancer Res. 2005, 11, 814-825.
16. Heaton, D. W.; Dines, S.; Dowell, R. S. High purity N-[4-[N,N-bis(2- iodoethyl)amino]phenoxycarbonyl]-L-glutamic acid and hydrogen iodide salt as prodrugs for ADEPT therapy. In PCT Int. Appl. WO 9620169, 1996.
17. 2) required: C, 67.52; H, 9.57; N, 2.72; found C, 67.09; H, 9.41; N, 2.69.
18. 2) required: C, 62.06; H, 10.18; N, 3.29; found C, 61.69; H, 9.79; N, 3.10.
19. arom3+5, J = 9.03 Hz), 7.87 (d, 1H, NH, J = 7.85 Hz).
20. 5